Pharmaceutical major Glenmark Pharma, on 18 October, announced the launch of a Triple-drug FDC (fixed drug combination) of Teneligliptin + Dapagliflozin + Metformin in India for people with type 2 diabetes in adults and comorbidities.

The product will be sold under the name Zita DM and is priced at Rs 14 per tablet (per day) in India, which will reduce the daily cost of therapy by 30%.

The drug will help in enhancing glycemic regulation in adult patients who have a high level of hyperbolic acid and/or are co-infected with other conditions. The drug is also for those whose diabetes is not managed through metformin therapy and those who necessitate the addition of Teneligliptin and Dapagliflozin as a single-dose combination to improve adherence to a single-dose pill.

Alok Malik, President & Business Head ‐ India Formulations of Glenmark Pharma, said, “Being a leader in treating diabetes, we are proud to introduce Zita DM, a novel and affordable anti-diabetic drug, which helps improve the glycemic control among adult patients with high HbA1c and other comorbidities; while also reducing major renal and cardiac adverse events. With this robust profile, we are positive Zita DM will facilitate patient adherence to chronic diabetes treatments.”

The company’s Zita portfolio of medicine serves around 1.75 million type 2 diabetes patients every year in India.